

**Sage  
Affordability**

*We provide infusion care  
at the most affordable  
cost.*



**Sage  
Support**

*We secure all available  
financial support & don't  
charge extra fees.*



**PROVEN  
PATIENT  
VALUE**

Typical Patient Cost Per Appointment

Drug List	Sage Price <sup>1</sup>	Financial Assistance Available <sup>2</sup>	Extra Fees <sup>3</sup>	Commercial Insurance <sup>4</sup>	Medicare <sup>5</sup>	Medicare Advantage <sup>6</sup>
Abilify Maintena	\$3,143	\$8,000	\$0	<50	\$0	\$604
Aristada Initio	\$3,839	\$2,000	\$0	<50	\$0	\$738
Brixadi (QM)	\$1,815	\$20,496	\$0	<50	\$0	\$349
Brixadi (QW)	\$454	\$20,496	\$0	<50	\$0	\$87
Fluphenazine decanoate	\$837	\$0	\$0	<100	\$0	\$161
Haloperidol decanoate	\$2,127	\$0	\$0	<100	\$0	\$409
Invega Hafyera	\$15,321	\$8,000	\$0	<50	\$0	\$2,946
Invega Sustenna	\$636	\$8,000	\$0	<50	\$0	\$122
Invega Trinza	\$15,321	\$8,000	\$0	<50	\$0	\$2,946
Risperdal Consta	\$151	\$5,500	\$0	<50	\$0	\$29
Spravato (1st)	\$934	\$8,150	\$0	<50	\$0	\$180
Spravato (subseq.)	\$1,301	\$8,150	\$0	<50	\$0	\$250
Uzedy	\$1,352	\$9,200	\$0	<50	\$0	\$260
Vivitrol	\$1,742	\$6,000	\$0	<50	\$0	\$335
Zyprexa Relprevv	\$716	TBD	\$0	<50	\$0	\$138

Sage accepts coverage from the following health insurances:



Prices listed are for Q1 2026

1. Sage low price reflects a 10% mark up from the government-controlled Medicare Price. Subject to quarterly change. Price can vary depending on order dose & patient weight.
2. Sage works on behalf of our patients to secure this assistance for out-of-pocket expenses. Listed is the maximum financial assistance for each drug available to each patient per year. Per Federal Law, assistance is not available to government-sponsored insurance like Medicare.
3. Sage Elevate doesn't charge for office visits, consultations, extra labs, or pre-meds (i.e. Tylenol).
4. Excludes deductible responsibility, if applicable, and assumes co-pay coverage, if available.
5. Medicare estimate assuming patient has supplemental coverage.
6. Medicare Advantage members typically have 20% co-insurance responsibility for infused drugs until out of pocket max is reached (\$9,250 for 2026). Once out-of-pocket max is reached, patient responsibility = \$0.